157 related articles for article (PubMed ID: 23251003)
1. Breast cancer stem cells: we've got them surrounded.
Korkaya H; Wicha MS
Clin Cancer Res; 2013 Feb; 19(3):511-3. PubMed ID: 23251003
[TBL] [Abstract][Full Text] [Related]
2. Targeting CXCR1/2 significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and -independent mechanisms.
Singh JK; Farnie G; Bundred NJ; Simões BM; Shergill A; Landberg G; Howell SJ; Clarke RB
Clin Cancer Res; 2013 Feb; 19(3):643-56. PubMed ID: 23149820
[TBL] [Abstract][Full Text] [Related]
3. Recent advances reveal IL-8 signaling as a potential key to targeting breast cancer stem cells.
Singh JK; Simões BM; Howell SJ; Farnie G; Clarke RB
Breast Cancer Res; 2013; 15(4):210. PubMed ID: 24041156
[TBL] [Abstract][Full Text] [Related]
4. The evaluation of the distribution of CD133, CXCR1 and the tumor associated macrophages in different molecular subtypes of breast cancer.
Ilgın C; Çomut E; Sarıgül Ç; Korkmaz S; Vardar E; Müftüoğlu SF
Histol Histopathol; 2020 Jan; 35(1):83-96. PubMed ID: 31250425
[TBL] [Abstract][Full Text] [Related]
5. An updated review on the role of the CXCL8-CXCR1/2 axis in the progression and metastasis of breast cancer.
Mishra A; Suman KH; Nair N; Majeed J; Tripathi V
Mol Biol Rep; 2021 Sep; 48(9):6551-6561. PubMed ID: 34426905
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-8, but not the Related Chemokine CXCL1, Sustains an Autocrine Circuit Necessary for the Properties and Functions of Thyroid Cancer Stem Cells.
Liotti F; Collina F; Pone E; La Sala L; Franco R; Prevete N; Melillo RM
Stem Cells; 2017 Jan; 35(1):135-146. PubMed ID: 27577959
[TBL] [Abstract][Full Text] [Related]
7. A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer.
Goldstein LJ; Perez RP; Yardley D; Han LK; Reuben JM; Gao H; McCanna S; Butler B; Ruffini PA; Liu Y; Rosato RR; Chang JC
Breast Cancer Res; 2020 Jan; 22(1):4. PubMed ID: 31924241
[TBL] [Abstract][Full Text] [Related]
8. An autocrine inflammatory forward-feedback loop after chemotherapy withdrawal facilitates the repopulation of drug-resistant breast cancer cells.
Jia D; Li L; Andrew S; Allan D; Li X; Lee J; Ji G; Yao Z; Gadde S; Figeys D; Wang L
Cell Death Dis; 2017 Jul; 8(7):e2932. PubMed ID: 28703802
[TBL] [Abstract][Full Text] [Related]
9. Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases.
Ha H; Debnath B; Neamati N
Theranostics; 2017; 7(6):1543-1588. PubMed ID: 28529637
[TBL] [Abstract][Full Text] [Related]
10. The CXCL8-CXCR1/2 pathways in cancer.
Liu Q; Li A; Tian Y; Wu JD; Liu Y; Li T; Chen Y; Han X; Wu K
Cytokine Growth Factor Rev; 2016 Oct; 31():61-71. PubMed ID: 27578214
[TBL] [Abstract][Full Text] [Related]
11. Expression of the chemokine receptors CXCR1 and CXCR2 in rat oligodendroglial cells.
Nguyen D; Stangel M
Brain Res Dev Brain Res; 2001 May; 128(1):77-81. PubMed ID: 11356265
[TBL] [Abstract][Full Text] [Related]
12. IL-8 promotes HNSCC progression on CXCR1/2-meidated NOD1/RIP2 signaling pathway.
Chan LP; Wang LF; Chiang FY; Lee KW; Kuo PL; Liang CH
Oncotarget; 2016 Sep; 7(38):61820-61831. PubMed ID: 27557518
[TBL] [Abstract][Full Text] [Related]
13. Targeting CXCR1 on breast cancer stem cells: signaling pathways and clinical application modelling.
Brandolini L; Cristiano L; Fidoamore A; De Pizzol M; Di Giacomo E; Florio TM; Confalone G; Galante A; Cinque B; Benedetti E; Ruffini PA; Cifone MG; Giordano A; Alecci M; Allegretti M; Cimini A
Oncotarget; 2015 Dec; 6(41):43375-94. PubMed ID: 26517518
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of CXCR1/CXCR2 on mesenchymal stromal cells may be an effective treatment for acute myocardial infarction.
Xu J; Chen Q; Shi C; Yin Z
Cytotherapy; 2009; 11(8):990-1. PubMed ID: 19929462
[TBL] [Abstract][Full Text] [Related]
15. IL-8, IL-8RA (CXCR1) and IL-8RB (CXCR2) expression in pilomatricoma.
Cianga CM; Cianga P; Dumitrescu GF; Sava A
Rom J Morphol Embryol; 2016; 57(1):59-64. PubMed ID: 27151689
[TBL] [Abstract][Full Text] [Related]
16. Cysteine-rich 61 (CCN1) enhances chemotactic migration, transendothelial cell migration, and intravasation by concomitantly up-regulating chemokine receptor 1 and 2.
Lin BR; Chang CC; Chen LR; Wu MH; Wang MY; Kuo IH; Chu CY; Chang KJ; Lee PH; Chen WJ; Kuo ML; Lin MT
Mol Cancer Res; 2007 Nov; 5(11):1111-23. PubMed ID: 18025257
[TBL] [Abstract][Full Text] [Related]
17. Multiple anti-tumor effects of Reparixin on thyroid cancer.
Liotti F; De Pizzol M; Allegretti M; Prevete N; Melillo RM
Oncotarget; 2017 May; 8(22):35946-35961. PubMed ID: 28415590
[TBL] [Abstract][Full Text] [Related]
18. Expression of interleukin-8 receptors in endometriosis.
Ulukus M; Ulukus EC; Seval Y; Zheng W; Arici A
Hum Reprod; 2005 Mar; 20(3):794-801. PubMed ID: 15618253
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-8-induced proliferation, survival, and MMP production in CXCR1 and CXCR2 expressing human umbilical vein endothelial cells.
Li A; Dubey S; Varney ML; Singh RK
Microvasc Res; 2002 Nov; 64(3):476-81. PubMed ID: 12453441
[No Abstract] [Full Text] [Related]
20. CXCL8 and its cognate receptors in melanoma progression and metastasis.
Singh S; Singh AP; Sharma B; Owen LB; Singh RK
Future Oncol; 2010 Jan; 6(1):111-6. PubMed ID: 20021212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
